No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate‐to‐severe plaque psoriasis

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2133|178|2|e105-e107

ISSN： 0007-0963

Source： BRITISH JOURNAL OF DERMATOLOGY, Vol.178, Iss.2, 2018-02, pp. : e105-e107

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 1, 2018-01 ,pp. : 132-139

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pruritus and quality of life in moderate‐to‐severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 6, 2015-06 ,pp. : 1114-1120

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies

By  

Psychotherapy and Psychosomatics, Vol. 86, Iss. 5, 2017-09 ,pp. : 260-267

Karger

Access to resources Recommend Favorite

Adalimumab in the treatment of moderate‐to‐severe chronic plaque psoriasis in patients switching from other biologics

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 9, 2015-09 ,pp. : 1742-1749

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1562-1574

John Wiley & Sons Inc

Access to resources Recommend Favorite